Loading…
Reported covered position: Int Rep. Coble (2008); Int Com on E&C (2011); SA Rep. Stearns (2012); Int LC L Concl. Rep. Bilirakis (2014-2016); L Concl. LD Rep. Griffith (2016-2019); Concl Com on E&C (2019-2023)
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Unmet medical need in acute pain; H.R. 1227/S. 475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease; Drug Pricing Policies including Most Favored Nation policy proposals.
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2026 · third_quarter · Q3
Unmet medical need in acute pain; H.R. 1227/S. 475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease; Drug Pricing Policies including Most Favored Nation policy proposals.
Issues related to Sec. 232 pharmaceutical tariffs, onshoring active pharmaceutical ingredients (API), and supply chain disruptions for products related to the opioid public health emergency.
Source: Senate LDA
Unmet medical need in acute pain; H.R. 1227/S. 475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease; Drug Pricing Policies including Most Favored Nation policy proposals.
New Era of Preventing End-Stage Kidney Disease Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, H.R. 6423/S. 864 - HELP Copays Act; Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1 and H.R. 1518 - New Era of Preventing End-Stage Kidney Disease; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
New Era of Preventing End-Stage Kidney Disease Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, H.R. 6423/S. 864 - HELP Copays Act; Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1 and H.R. 1518 - New Era of Preventing End-Stage Kidney Disease; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, H.R. 6423/S. 864 - HELP Copays Act; Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1 and H.R. 1518 - New Era of Preventing End-Stage Kidney Disease; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, H.R. 6423/S. 864 - HELP Copays Act; Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1 and H.R. 1518 - New Era of Preventing End-Stage Kidney Disease; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Unmet medical need in acute pain; H.R. 1227/S. 475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease; Drug Pricing Policies including Most Favored Nation policy proposals.
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Unmet medical need in acute pain; H.R. 1227/S. 475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease; Drug Pricing Policies including Most Favored Nation policy proposals.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, H.R. 6423/S. 864 - HELP Copays Act; Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1 and H.R. 1518 - New Era of Preventing End-Stage Kidney Disease; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, H.R. 6423/S. 864 - HELP Copays Act; Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1 and H.R. 1518 - New Era of Preventing End-Stage Kidney Disease; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Unmet medical need in acute pain; H.R.1227/S.475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease.
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Unmet medical need in acute pain; H.R. 1227/S. 475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease; Drug Pricing Policies including Most Favored Nation policy proposals; Issues regarding the One Big Beautiful Bill Act (PL 119-21).
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Unmet medical need in acute pain; H.R. 1227/S. 475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease; Drug Pricing Policies including Most Favored Nation policy proposals; Issues regarding the One Big Beautiful Bill Act (PL 119-21).
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Unmet medical need in acute pain; H.R. 1227/S. 475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease; Drug Pricing Policies including Most Favored Nation policy proposals.
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Unmet medical need in acute pain; H.R. 1227/S. 475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease; Drug Pricing Policies including Most Favored Nation policy proposals.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, H.R. 6423/S. 864 - HELP Copays Act; Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Unmet medical need in acute pain; H.R. 1227/S. 475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease; Drug Pricing Policies including Most Favored Nation policy proposals.
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Unmet medical need in acute pain; H.R.1227/S.475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease.
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Unmet medical need in acute pain; H.R. 1227/S. 475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease; Drug Pricing Policies including Most Favored Nation policy proposals.
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Unmet medical need in acute pain; H.R. 1227/S. 475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease; Drug Pricing Policies including Most Favored Nation policy proposals; Issues regarding the One Big Beautiful Bill Act (PL 119-21).
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Unmet medical need in acute pain; H.R. 1227/S. 475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease; Drug Pricing Policies including Most Favored Nation policy proposals; Issues regarding the One Big Beautiful Bill Act (PL 119-21).
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, S.864 - HELP Copays Act; Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, S.864 - HELP Copays Act; Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, HELP Copays Act (S.864); Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, H.R. 6423/S. 864 - HELP Copays Act; Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, S.864 - HELP Copays Act; Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
BIOSECURE Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); General education about Alternative Funding Programs; General education about kidney disease, including APOL-1; H.R. 7085 - the BIOSECURE Act.
BIOSECURE Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); General education about Alternative Funding Programs; General education about kidney disease, including APOL-1; H.R. 7085 - the BIOSECURE Act; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; H.R. 7142/S. 3832 - The Alternatives to PAIN Act.
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); General education about Alternative Funding Programs; General education about kidney disease, including APOL-1; H.R. 7085 - the BIOSECURE Act; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; H.R. 7142/S. 3832 - The Alternatives to PAIN Act.
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Implementation of P.L. 117-169 provisions related to Medicare prescription drugs; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; H.R. 7142/S. 3832 - The Alternatives to PAIN Act.
McIntire-Stennis Act District of Columbia Equality Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Unmet medical need in acute pain; H.R.7421/S.3832 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning.
McIntire-Stennis Act District of Columbia Equality Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Unmet medical need in acute pain; H.R.7421/S.3832 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); General education about Alternative Funding Programs; General education about kidney disease, including APOL-1; H.R. 7085 - the BIOSECURE Act.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; Genetic kidney disease, including APOL-1; Ex-US access to innovative medicines; Cystic Fibrosis; Sickle cell disease.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); General education about Alternative Funding Programs; General education about kidney disease, including APOL-1; H.R. 7085 - the BIOSECURE Act; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; H.R. 7142/S. 3832 - The Alternatives to PAIN Act.
Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2025
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Access to non-opioids in DoD/Tricare (H.R.8774/S.4921 - Department of Defense Appropriations Act, 2025); Access to non-opioids in VHA and general support for clinical trial operations at VHA to address high prevalence diseases and conditions (H.R.8580/S.4677 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2025); Access to non-opioids for Medicare beneficiaries and education about risk of kidney disease amongst minority populations (H.R.9029/S.4942 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025).
Department of Defense Appropriations Act, 2025
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Access to non-opioids in DoD/Tricare (H.R.8774/S.4921 - Department of Defense Appropriations Act, 2025); Access to non-opioids in VHA and general support for clinical trial operations at VHA to address high prevalence diseases and conditions (H.R.8580/S.4677 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2025); Access to non-opioids for Medicare beneficiaries and education about risk of kidney disease amongst minority populations (H.R.9029/S.4942 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025).
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Access to non-opioids in DoD/Tricare (H.R.8774/S.4921 - Department of Defense Appropriations Act, 2025); Access to non-opioids in VHA and general support for clinical trial operations at VHA to address high prevalence diseases and conditions (H.R.8580/S.4677 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2025); Access to non-opioids for Medicare beneficiaries and education about risk of kidney disease amongst minority populations (H.R.9029/S.4942 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025).
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); General education about Alternative Funding Programs; General education about kidney disease, including APOL-1; H.R. 7085 - the BIOSECURE Act; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; H.R. 7142/S. 3832 - The Alternatives to PAIN Act.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; Genetic kidney disease, including APOL-1; Ex-US access to innovative medicines; Cystic Fibrosis; Sickle cell disease.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); General education about Alternative Funding Programs; General education about kidney disease, including APOL-1; H.R. 7085 - the BIOSECURE Act.
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Unmet medical need in acute pain; H.R.7421/S.3832 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease.
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Unmet medical need in acute pain; H.R.7421/S.3832 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning.
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Implementation of P.L. 117-169 provisions related to Medicare prescription drugs; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; H.R. 7142/S. 3832 - The Alternatives to PAIN Act.
Alternatives to PAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); General education about Alternative Funding Programs; General education about kidney disease, including APOL-1; H.R. 7085 - the BIOSECURE Act; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; H.R. 7142/S. 3832 - The Alternatives to PAIN Act.
Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2025
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Access to non-opioids in DoD/Tricare (H.R.8774/S.4921 - Department of Defense Appropriations Act, 2025); Access to non-opioids in VHA and general support for clinical trial operations at VHA to address high prevalence diseases and conditions (H.R.8580/S.4677 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2025); Access to non-opioids for Medicare beneficiaries and education about risk of kidney disease amongst minority populations (H.R.9029/S.4942 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025).
Department of Defense Appropriations Act, 2025
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Access to non-opioids in DoD/Tricare (H.R.8774/S.4921 - Department of Defense Appropriations Act, 2025); Access to non-opioids in VHA and general support for clinical trial operations at VHA to address high prevalence diseases and conditions (H.R.8580/S.4677 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2025); Access to non-opioids for Medicare beneficiaries and education about risk of kidney disease amongst minority populations (H.R.9029/S.4942 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025).
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Access to non-opioids in DoD/Tricare (H.R.8774/S.4921 - Department of Defense Appropriations Act, 2025); Access to non-opioids in VHA and general support for clinical trial operations at VHA to address high prevalence diseases and conditions (H.R.8580/S.4677 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2025); Access to non-opioids for Medicare beneficiaries and education about risk of kidney disease amongst minority populations (H.R.9029/S.4942 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025).
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); General education about Alternative Funding Programs; Pandemic All-Hazards Preparedness Act reauthorization, including new authorities requested by FDA.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); General education about Alternative Funding Programs; Pandemic All-Hazards Preparedness Act reauthorization, including new authorities requested by FDA.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process; Copay accumulators and maximizers, HELP Copays Act (HR 830, S. 1375); General education about Alternative Funding Programs; Pandemic All-Hazards Preparedness Act reauthorization, including new authorities requested by FDA.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); General education about Alternative Funding Programs; Pandemic All-Hazards Preparedness Act reauthorization, including new authorities requested by FDA.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); General education about Alternative Funding Programs; Pandemic All-Hazards Preparedness Act reauthorization, including new authorities requested by FDA.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process; Copay accumulators and maximizers, HELP Copays Act (HR 830, S. 1375); General education about Alternative Funding Programs; Pandemic All-Hazards Preparedness Act reauthorization, including new authorities requested by FDA.
Issues related to veteran's access to non-opioid alternatives and implementation of report language in the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026 (PL 119-37).
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, H.R. 6423/S. 864 - HELP Copays Act; Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1 and H.R. 1518 - New Era of Preventing End-Stage Kidney Disease; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
Education about non-opioid pain therapies and patient access to non-opioid medicines, updates on coverage progress at the VHA and CMS.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Congressional Budget Office (CBO), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, Vice President of the U.S., White House Office
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2026 · second_quarter · Q2
Issues related to veteran's access to non-opioid alternatives and implementation of report language in the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026 (PL 119-37).
Issues related to Sec. 232 pharmaceutical tariffs, onshoring active pharmaceutical ingredients (API), and supply chain disruptions for products related to the opioid public health emergency.
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, H.R. 6423/S. 864 - HELP Copays Act; Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1 and H.R. 1518 - New Era of Preventing End-Stage Kidney Disease; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
Education about non-opioid pain therapies and patient access to non-opioid medicines, updates on coverage progress at the VHA and CMS.
Unmet medical need in acute pain; H.R. 1227/S. 475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease; Drug Pricing Policies including Most Favored Nation policy proposals.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Congressional Budget Office (CBO), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, Vice President of the U.S., White House Office
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2025 · fourth_quarter · Q4
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, H.R. 6423/S. 864 - HELP Copays Act; Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
Unmet medical need in acute pain; H.R. 1227/S. 475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease; Drug Pricing Policies including Most Favored Nation policy proposals.
Education about non-opioid pain therapies and patient access to non-opioid medicines; Education on alternative funding programs; Education on the Million Veteran Program at the VA.
Issues related to the National Defense Authorization Act - access to non-opioids for service members and their families; Issues related to the NDAA S.Amdt.3841 BIOSECURE Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, U.S. Trade Representative (USTR), Vice President of the U.S., White House Office
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2025 · third_quarter · Q3
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, S.864 - HELP Copays Act; Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
Unmet medical need in acute pain; H.R. 1227/S. 475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease; Drug Pricing Policies including Most Favored Nation policy proposals.
Education about non-opioid pain therapies and patient access to non-opioid medicines; Education on alternative funding programs; Education on the Million Veteran Program at the VA.
Issues related to the National Defense Authorization Act - access to non-opioids for service members and their families; Issues related to the NDAA S.Amdt.3841 BIOSECURE Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, U.S. Trade Representative (USTR), Vice President of the U.S., White House Office
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2025 · second_quarter · 2A
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, S.864 - HELP Copays Act; Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
Unmet medical need in acute pain; H.R. 1227/S. 475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease; Drug Pricing Policies including Most Favored Nation policy proposals; Issues regarding the One Big Beautiful Bill Act (PL 119-21).
Education about non-opioid pain therapies and patient access to non-opioid medicines; Education on alternative funding programs; Education on the Million Veteran Program at the VA.
Issues related to the National Defense Authorization Act - access to non-opioids for service members and their families.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Congressional Budget Office (CBO), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), White House Office
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2025 · second_quarter · Q2
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, S.864 - HELP Copays Act; Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
Unmet medical need in acute pain; H.R. 1227/S. 475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease; Drug Pricing Policies including Most Favored Nation policy proposals; Issues regarding the One Big Beautiful Bill Act (PL 119-21).
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2025 · first_quarter · Q1
Unmet medical need in acute pain; H.R.1227/S.475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease.
Education about non-opioid pain therapies and patient access to non-opioid medicines, education on alternative funding programs, education on the Million Veteran Program at the VA.
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, HELP Copays Act (S.864); Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2024 · fourth_quarter · Q4
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.
Unmet medical need in acute pain; H.R.7421/S.3832 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2024 · third_quarter · Q3
Access to non-opioids in DoD/Tricare (H.R.8774/S.4921 - Department of Defense Appropriations Act, 2025); Access to non-opioids in VHA and general support for clinical trial operations at VHA to address high prevalence diseases and conditions (H.R.8580/S.4677 - Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2025); Access to non-opioids for Medicare beneficiaries and education about risk of kidney disease amongst minority populations (H.R.9029/S.4942 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025).
Unmet medical need in acute pain; H.R.7421/S.3832 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning.
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2024 · second_quarter · Q2
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; Medicaid Program; Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program.
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); General education about Alternative Funding Programs; General education about kidney disease, including APOL-1; H.R. 7085 - the BIOSECURE Act; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; H.R. 7142/S. 3832 - The Alternatives to PAIN Act.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2024 · first_quarter · Q1
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); General education about Alternative Funding Programs; General education about kidney disease, including APOL-1; H.R. 7085 - the BIOSECURE Act.
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Implementation of P.L. 117-169 provisions related to Medicare prescription drugs; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; H.R. 7142/S. 3832 - The Alternatives to PAIN Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2023 · fourth_quarter · Q4
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Implementation of P.L. 117-169 provisions related to Medicare prescription drugs; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; Medicaid Program; Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program.
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); General education about Alternative Funding Programs; Pandemic All-Hazards Preparedness Act reauthorization, including new authorities requested by FDA.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2023 · third_quarter · Q3
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); General education about Alternative Funding Programs; Pandemic All-Hazards Preparedness Act reauthorization, including new authorities requested by FDA.
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Implementation of P.L. 117-169 provisions related to Medicare prescription drugs; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; Medicaid Program; Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2023 · second_quarter · Q2
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process; Copay accumulators and maximizers, HELP Copays Act (HR 830, S. 1375); General education about Alternative Funding Programs; Pandemic All-Hazards Preparedness Act reauthorization, including new authorities requested by FDA.
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Implementation of P.L. 117-169 provisions related to Medicare prescription drugs. Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Education about non-opioid pain therapies and patient access to non-opioid medicines; Education on alternative funding programs; Education on the Million Veteran Program at the VA.
Issues related to the National Defense Authorization Act - access to non-opioids for service members and their families.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Congressional Budget Office (CBO), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), White House Office
Filing targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE, White House Office
Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; Genetic kidney disease, including APOL-1; Ex-US access to innovative medicines; Cystic Fibrosis; Sickle cell disease.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE